The quarter was mixed against expectations, not a clean beat. Non-GAAP EPS of $1.15 exceeded the published consensus of roughly $1.12, but revenue of $1.066 billion fell short of expectations near $1.10 billion.
| Metric | Q3 2026 | Q3 2025 / expectation |
|---|---|---|
| Revenue | $1,066.2M (Income Statement) | $1,060.3M prior year; ~$1.10B consensus |
| Non-GAAP diluted EPS | $1.15 (GAAP to non-GAAP reconciliation) | $1.10 prior year; ~$1.12 consensus |
| Non-GAAP operating margin | 26% (GAAP to non-GAAP reconciliation) | 26% prior year |
| Organic revenue growth | 1% total; 0% CooperVision; 3% CooperSurgical (Segment results) | — |
| Share repurchases | $339.1M in Q3 (Share repurchase disclosure) | Authorization expanded to $3.0B |
The EPS beat was helped by cost control and a tax release, not stronger demand. Non-GAAP operating margin held at 26%, while GAAP EPS benefited heavily from the reversal of a $307.2 million tax reserve after the U.K. examination. The underlying revenue picture was much less impressive: total organic growth was only 1%, CooperVision was flat, and management said U.S. channel inventory reductions will continue to weigh on Q4. 〔0〕
The strategic review removes a potential breakup catalyst rather than creating one. The board evaluated selling CooperSurgical but concluded that offers were not attractive enough, so the business remains part of the company. 〔1〕 That outcome is partly known because the review and possible sale had already been disclosed; the new information is that no transaction cleared the board's valuation threshold.
Capital allocation is the clearest incremental positive. CooperCompanies expanded its repurchase authorization from $2 billion to $3 billion after buying back $339.1 million of shares during the quarter. This provides a tangible support to per-share results, but it does not offset the weaker demand signal from flat CooperVision growth and the explicit Q4 inventory headwind.
Net read: operationally in line, with a better EPS print offset by softer revenue and no CooperSurgical sale. The filing improves capital-return visibility and shows margin discipline, but the market still needs evidence that CooperVision can resume organic growth after the channel cleanup.
Read the original 8-K on SEC EDGAR ↗